Nitric oxide releasing lozenge for maintaining telomere length

Overview

This solution centers on a proprietary nitric oxide releasing lozenge that addresses the age-related decline in nitric oxide production, a key driver of endothelial dysfunction and telomere shortening. Nitric oxide is a naturally produced gaseous signaling molecule with a physiological half-life of less than one second. It initiates cellular responses including vasodilation, enhanced tissue oxygenation, stem cell mobilization, telomerase activation, and mitochondrial biogenesis. As nitric oxide production declines with age, telomerase expression and activity decrease, leading to progressive telomere shortening. The lozenge provides a bioactive source of nitric oxide that recapitulates endogenous signaling, improves endothelial function, and restores the oral microbiome. When the body cannot produce sufficient nitric oxide, the lozenge delivers a rescue dose while also supporting restoration of endogenous production.

The technology targets consumers and clinicians seeking science-backed approaches to anti-aging, cardiovascular wellness, and cellular health. By focusing on restoring nitric oxide rather than relying on precursor molecules such as L-Arginine, which may not be effectively converted by the body, the lozenge offers a direct pathway to improved vascular and cellular function.

Technical specifications

• Bioactive nitric oxide delivery: Patented delivery system designed to bypass traditional enzymatic pathways, allowing the body to produce or utilize nitric oxide directly
• Lozenge format: Oral delivery designed for convenient twice-daily dosing
• Mechanism of action: Restores nitric oxide signaling to improve endothelial function, activate telomerase, and support mitochondrial biogenesis
• Dual benefit model: Provides exogenous nitric oxide as a rescue dose while supporting restoration of endogenous nitric oxide production
• Oral microbiome support: Recapitulates natural signaling to restore the oral microbiome in addition to systemic benefits
• Anecdotal evidence: Individual patients monitoring telomere length have reported improvement after using the lozenge

Technology readiness level

The nitric oxide releasing lozenge is currently in an early-to-mid stage of development with respect to telomere length validation. Anecdotal evidence from patients monitoring their telomere length suggests improvement after lozenge use, but no randomized, placebo-controlled clinical trials have been completed. The planned validation includes a randomized, placebo-controlled clinical trial enrolling 40 subjects aged 40 to 60, providing either the nitric oxide lozenge or a placebo twice daily for six months. Baseline and post-intervention blood analysis will measure telomere length to determine efficacy compared to placebo. The broader product line has undergone clinical study for related wellness markers such as skin texture and circulatory efficiency, and the company currently markets proprietary nitric oxide-based products including lozenges, serums, and cleansers through direct-to-consumer and wholesale channels.